Today, virtual reality pioneer Oxford VR has announced the closure of a landmark $12.5 million Series A funding round—the largest investment funding for VR therapy in the UK and Europe. Oxford VR’s first clinical trial for fear of heights, which was published in The Lancet Psychiatry, shows how automated VR therapy can produce large clinical benefits. Oxford VRIn VR therapy, individuals put on a headset and enter VR simulations of the situations and environments that trigger their symptoms. The great thing about VR therapy is that the behavioural changes made in the VR environment transfer to the real world. Plus, VR therapy is automated, so therapists can be redeployed to more urgent cases or other aspects of care.

Source: Forbes February 12, 2020 11:37 UTC